Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viloxazine ER (AK-D101) in Korean Children and Adolescents With ADHD
NCT07678827Phase 3Not yet recruiting
- Sponsor
- Alvogen
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 3 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Alvogen. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07678827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678827.